Multiple Myeloma Frontline Treatment: How to Choose
A clear patient guide to 4-drug and 3-drug frontline regimens, how they work, and which option fits your health profile
Medical Disclaimer: This guide is synthesized from international clinical consensus guidelines and peer-reviewed literature. It is for educational purposes only and does not substitute for professional medical advice. Always consult your oncology team regarding diagnostic and treatment decisions.
💡 The Short Answer
Your first treatment plan—called frontline therapy—is your single best opportunity to achieve a deep, multi-year remission. Under the latest NCCN (v2.2027) and EHA-EMN (2025) guidelines, 4-drug quadruplets—Dara-VRd (84.3% 4-year progression-free survival in PERSEUS; 68.1% 54-month progression-free survival in CEPHEUS) and Isa-VRd (63.2% 5-year progression-free survival in IMROZ)—are the Category 1 preferred frontline regimens for transplant-eligible and fit non-transplant patients under age 80. For frail or older adults (age ≥ 80), 3-drug Dara-Rd (61.9-month median progression-free survival in MAIA) or steroid-sparing Dara-R (53.4-month median progression-free survival in IFM2017-03, stopping dexamethasone after Cycle 2) are preferred, while carfilzomib-based quads (Isa-KRd/Dara-KRd) and kidney-safe Dara-VCd/VCd match specific genetic, nerve, cardiac, and renal profiles.
Why This Matters
Walking into your first oncology visit can feel like trying to read a foreign code: doctors talk about Dara-VRd, Isa-VRd, Dara-Rd, VRd, and Isa-KRd. Before you choose a plan with your care team, three reassuring truths can clear away the confusion:
- Four-drug combinations have replaced older three-drug regimens for most fit patients: Adding a targeted anti-CD38 antibody (daratumumab or isatuximab) to the classic 3-drug VRd backbone nearly doubles the rate of sustained Minimal Residual Disease (MRD) negativity without adding traditional chemotherapy hair loss or severe nausea.
- Older or frail patients do not need four heavy drugs to get a 5-year remission: If you are over 80 or physically frail, the 3-drug Dara-Rd regimen (or steroid-sparing Dara-R) controls myeloma for over 4.4 to 5.1 years on average while keeping side effects gentle.
- There is no single "best" regimen—only the best match for your organs: If you already have numb fingers from diabetes, heart trouble, acute kidney injury, or high-risk genetics, your doctor can swap individual drugs in the formula to protect your body.
This guide decodes the drug abbreviations, compares the leading frontline regimens side by side, and shows how doctors match the right combination to your profile.
📖 Key Terms in Plain English
| Term | Plain-English Meaning |
|---|---|
| Quadruplet ("Quad") vs. Triplet | A 4-drug frontline combination (such as Dara-VRd or Isa-VRd) versus a 3-drug combination (such as Dara-Rd or VRd) |
| Anti-CD38 Antibody (Dara or Isa) | A targeted immunotherapy (daratumumab or isatuximab) that locks onto the CD38 protein on myeloma cells so your immune system can wipe them out |
| Proteasome Inhibitor (V or K) | A drug (bortezomib or carfilzomib) that clogs the myeloma cell's internal "garbage disposal" so toxic proteins build up inside the tumor cell |
| IMiD (Lenalidomide / R) | An oral immune-modulating capsule that wakes up your T-cells and starves the tumor's blood supply |
| PFS (Progression-Free Survival) | How long a patient stays in remission on average before the myeloma starts growing again |
| Peripheral Neuropathy (PN) | Tingling, numbness, or "pins and needles" in the fingers or toes, most commonly caused by bortezomib (V) |
1. Decoding the Alphabet Soup: How Myeloma Regimens Are Built
Every modern frontline regimen is built from four simple drug families working together like a coordinated team:
| Letter Code | Drug Name & Class | How It Works in Plain Terms | How You Take It & Side Effects to Watch |
|---|---|---|---|
| Dara or Isa | Daratumumab (Dara) or Isatuximab (Isa) — Anti-CD38 Antibodies | Acts like a GPS-guided beacon that attaches to CD38 on myeloma cells and flags them for destruction | • Dara: 5-minute shot under the belly skin; Isa: IV drip; • Watch for: Mild first-dose fever/chills and lower respiratory immunity |
| V or K | Bortezomib (V) or Carfilzomib (K) — Proteasome Inhibitors | Blocks the tumor cell's protein-recycling pump so excess M-protein bursts the myeloma cell from within | • V: Weekly shot under the skin; Watch for finger/toe tingling; • K: IV drip; Almost zero nerve tingling, but requires heart and blood pressure checks |
| R or C | Lenalidomide (R, an IMiD) or Cyclophosphamide (C, an alkylator) | R boosts immune T-cells to attack myeloma; C is used temporarily when kidneys are acutely injured | • R: Oral capsule (14 or 21 days on, 7 days off); Watch for low blood counts, rash, and blood clots (requires aspirin or a blood thinner) |
| d | Dexamethasone (d) — Corticosteroid | Rapidly cools bone inflammation and boosts the cell-killing power of the other drugs | • Oral tablets or IV once weekly; • Watch for: Dose-day insomnia, next-day fatigue, ankle swelling, and blood sugar spikes |
What This Means for You: Almost every frontline regimen starts with the Rd foundation (lenalidomide + dexamethasone). Adding 1 drug creates a 3-drug triplet (Dara-Rd or VRd). Adding both a proteasome inhibitor (V or K) and an anti-CD38 antibody (Dara or Isa) creates a 4-drug quadruplet (Dara-VRd, Isa-VRd, or Isa-KRd).
Data Sources: NCCN Guidelines v2.2027; EHA-EMN 2025 Guidelines.
2. Comparing Recommended Frontline Regimens (NCCN v2.2027 & EHA-EMN 2025)
2.1 Four-Drug Quadruplets: The Standard of Care for Fit Patients
For transplant-eligible patients and fit non-transplant patients under age 80, four-drug combinations deliver the deepest remissions ever recorded in myeloma:
| Quadruplet Regimen | Guideline Status & Trials | Landmark Efficacy Data | Practical Pros & Cons |
|---|---|---|---|
| 1. Dara-VRd (Daratumumab + Bortezomib + Lenalidomide + Dex) | NCCN Category 1 Preferred (PERSEUS for transplant; CEPHEUS for fit non-transplant) | • Transplant (PERSEUS): 84.3% progression-free at 4 years (vs. 67.7% with VRd, cutting progression/death risk by 58%), 75.2% MRD-negative; • Non-transplant (CEPHEUS): 68.1% progression-free at 54 months, 60.9% MRD-negative | • Pros: Fast 5-minute subcutaneous Dara shot; strongest long-term survival data across both settings; • Cons: Requires monitoring for bortezomib nerve tingling |
| 2. Isa-VRd (Isatuximab + Bortezomib + Lenalidomide + Dex) | NCCN Category 1 Preferred (GMMG-HD7 for transplant; IMROZ for fit non-transplant) | • Transplant (GMMG-HD7): 66% post-transplant MRD-negative (vs. 48% with VRd), 30% lower progression risk; • Non-transplant (IMROZ): 63.2% progression-free at 5 years (vs. 45.2% with VRd), 74.7% Complete Response | • Pros: Equally powerful Category 1 peer to Dara-VRd; weekly bortezomib schedule (BENEFIT trial) lowers nerve side effects; • Cons: Isatuximab is given by IV infusion |
| 3. Isa-KRd or Dara-KRd (Carfilzomib-Based Quads) | NCCN Other Recommended / High-Risk Option (IsKia and GMMG-CONCEPT trials) | • IsKia Trial: 77% 10⁻⁵ MRD-negative overall, and 72% ultra-deep 10⁻⁶ MRD-negative in high-risk genetics; • CONCEPT Trial: 67.7% MRD-negative in high-risk patients | • Pros: Exceptional depth of response in high-risk genetics; very low nerve tingling (< 6% Grade 2+); • Cons: IV carfilzomib requires baseline heart ultrasound (echocardiogram) |
What This Means for You: Patients often wonder whether Dara-VRd or Isa-VRd is stronger. Both are Category 1 gold standards with virtually identical tumor-clearing power. Choosing between them usually depends on convenience (a 5-minute belly shot with daratumumab versus an IV infusion with isatuximab) and which antibody your clinic and insurance cover best.
2.2 Three-Drug Triplets & Steroid-Sparing Regimens: Gentler Power When Needed
For older adults, frail patients, or special clinical situations, these three-drug combinations provide durable disease control without four-drug toxicity:
| Triplet Regimen | Guideline Status & Trials | Landmark Efficacy Data | When Doctors Prefer It |
|---|---|---|---|
| 1. Dara-Rd (Daratumumab + Lenalidomide + Dex) | NCCN Category 1 Preferred for Non-Transplant (MAIA trial) | • Median Progression-Free Survival (PFS): 61.9 months (over 5.1 years, vs. 34.4 months with Rd); • 5-year Overall Survival: 66.6%, with 92.9% overall response rate | • Top choice for frail or older non-transplant patients, or anyone needing to avoid bortezomib nerve tingling while still gaining a 5+ year average remission |
| 2. Steroid-Sparing Dara-R (Stops Dex After Cycle 2) | EHA-EMN 2025 Recommended for Frail Patients (IFM2017-03 trial) | • Median PFS: 53.4 months (vs. 22.5 months with Rd), cutting death risk by 54%; • Severe infection rate kept low (19%) | • Ideal for frail or elderly patients (age ≥ 80): stops dexamethasone completely after 2 cycles, avoiding steroid insomnia, muscle wasting, and blood sugar spikes |
| 3. Classic VRd or VRd-lite (Bortezomib + Lenalidomide + Dex) | NCCN Category 1 Other Recommended (SWOG S0777 trial) | • Median PFS: 41 to 52.6 months; • Median Overall Survival: > 84 months (> 7 years); • VRd-lite uses gentler doses for older adults | • Reliable Category 1 backup when anti-CD38 antibodies (Dara/Isa) are unavailable or restricted by insurance coverage |
| 4. Dara-VCd or VCd (Uses Cyclophosphamide Instead of Lenalidomide) | NCCN Useful in Certain Circumstances (Acute Kidney Failure) | • Overall Response Rate: 85% to 88%; • Rapidly clears toxic free light chains from kidney tubules without relying on kidney clearance | • Emergency starting regimen for acute kidney injury (serum creatinine > 2.0 mg/dL [> 177 μmol/L] or eGFR < 30 mL/min); switched to Dara-VRd once kidneys recover |
Data Sources: NCCN Guidelines v2.2027; EHA-EMN 2025 Guidelines; PERSEUS, CEPHEUS, GMMG-HD7, IMROZ, IsKia, MAIA, and IFM2017-03 Trials.
3. Patient-Matching Guide: Which Frontline Regimen Fits Your Profile?
Your oncologist matches your regimen by looking at your biological fitness (using the IMWG Frailty Score), your baseline FISH genetics, and your kidney, nerve, and heart health:
| Your Specific Patient Profile | Top Matched Regimen(s) | Why This Match Protects You Best |
|---|---|---|
| 1. Fit & Transplant-Eligible (Standard-Risk Genetics) | Dara-VRd or Isa-VRd (Category 1 Preferred) | Gives an 84%+ chance of staying progression-free at 4 years and maximizes Sustained MRD Negativity so you can step down to single-pill maintenance later |
| 2. High-Risk Genetics (2025 IMS/IMWG del(17p)/TP53, Double-Hit, or R2-ISS 3–5 pts) | Dara-VRd, Isa-VRd, or Carfilzomib-based Isa-KRd / Dara-KRd | High-risk clones require a 4-drug attack upfront (followed by autologous stem cell transplant and continuous 2-drug maintenance) to prevent early relapse |
| 3. Fit Non-Transplant (Typically Age 70–79, Independent in Daily Life) | Dara-VRd (CEPHEUS), Isa-VRd (IMROZ), or Dara-Rd (MAIA) | Fit older adults tolerate weekly-bortezomib 4-drug regimens well (63%–68% progression-free at 4.5–5 years), while Dara-Rd offers a gentler 3-drug option |
| 4. Frail or Age ≥ 80 (Needs Help with Daily Tasks or Multiple Illnesses) | Dara-Rd (MAIA) or Steroid-Sparing Dara-R (IFM2017-03) or VRd-lite | Avoids 4-drug over-treatment; stopping dexamethasone after Cycle 2 (Dara-R) prevents severe infections while preserving a 4.4-year median remission |
| 5. Acute Kidney Injury at Diagnosis (Creatinine > 2.0 mg/dL [> 177 μmol/L]) | Start with Dara-VCd or VCd (CyBorD), then switch to Dara-VRd | Bortezomib and daratumumab work at full dose without kidney adjustment, whereas lenalidomide is cleared by the kidneys and added after kidney recovery |
| 6. Pre-Existing Numbness / Neuropathy (From Diabetes or Spine Issues) | Dara-Rd (non-transplant) or Isa-KRd / Dara-KRd / KRd (transplant) | Replaces nerve-irritating bortezomib (V) with carfilzomib (K) or omits it entirely (Dara-Rd) to prevent painful nerve damage |
| 7. Pre-Existing Heart Failure, Arrhythmia, or Uncontrolled High Blood Pressure | Dara-VRd, Isa-VRd, or Dara-Rd (Avoid Carfilzomib) | Carfilzomib (K) carries a risk of fluid overload, hypertension, and heart strain, making bortezomib-based or Dara-Rd regimens much safer |
What This Means for You: Chronological age alone does not decide your regimen. A healthy, active 74-year-old often does wonderfully on a 4-drug regimen with weekly subcutaneous bortezomib, whereas a 66-year-old with severe diabetes and nerve numbness is much safer on Dara-Rd or a carfilzomib-based plan.
Always Ask for Once-Weekly Subcutaneous Bortezomib
Years ago, bortezomib (Velcade) was given twice a week through an IV vein, causing painful finger and toe numbness in more than half of patients. Today, guidelines strongly recommend giving bortezomib once a week as a tiny injection under the skin—it works just as well against myeloma while cutting nerve damage in half.
Data Sources: NCCN Guidelines v2.2027; EHA-EMN 2025 Guidelines; BENEFIT (IFM2020-05) Trial.
Common Pitfalls to Avoid
Pitfall 1: Trying to "Tough Out" Finger or Toe Tingling Without Telling Your Doctor
❌ The Pitfall: Hiding numb fingertips or "pins and needles" in your feet because you worry your oncologist will stop your myeloma treatment.
✅ The Right Move: Report even mild Grade 1 tingling at your very next clinic visit. Lowering the bortezomib dose or spacing out injections early allows your nerves to heal completely before permanent nerve pain develops.
Pitfall 2: Accepting Twice-Weekly or IV Bortezomib When Once-Weekly Subcutaneous Dosing Is Standard
❌ The Pitfall: Receiving bortezomib on an older twice-weekly schedule (Days 1, 4, 8, and 11) in routine practice, which sharply increases peripheral neuropathy and clinic fatigue.
✅ The Right Move: Unless you are in an acute hospital emergency (such as acute kidney cast nephropathy requiring rapid light-chain clearance in Cycle 1), ask your doctor for standard once-weekly subcutaneous bortezomib.
Pitfall 3: Starting Frontline Therapy Without the 3 Mandatory Companion Protectors
❌ The Pitfall: Taking Dara-VRd, Isa-VRd, or Dara-Rd without antiviral pills, blood-clot prevention, or bone-strengthening therapy, exposing yourself to shingles or blood clots.
✅ The Right Move: Ensure every frontline prescription includes daily acyclovir or valacyclovir (to prevent shingles), aspirin or an anticoagulant (to prevent lenalidomide-related blood clots), and zoledronic acid or denosumab (for bone protection).
Pitfall 4: Staying on Full-Dose Dexamethasone Despite Severe Insomnia or Blood Sugar Spikes
❌ The Pitfall: Suffering through sleepless nights, severe anxiety, ankle swelling, or uncontrolled diabetes because you assume full-dose 40 mg weekly dexamethasone is mandatory for the entire induction phase.
✅ The Right Move: Tell your care team whenever steroids disrupt your sleep, mood, or blood sugar. Reducing dexamethasone to 20 mg or 10 mg weekly—or stopping it after Cycle 2 in frail patients (Dara-R)—protects your quality of life without sacrificing remission depth.
Summary: Your Quick Decision Guide
Frontline Regimen Selection & Organ-Matching Pathway
Select your clinical profile or switch inside any card to compare NCCN v2.2027 & EHA-EMN 2025 frontline options:
4-Drug Quadruplets
84.3% 4-yr PFS (transplant) · 5-min belly shot
63.2% 5-yr PFS (non-transplant) · IV anti-CD38
4–8 induction cycles → step down to maintenance
3-Drug & Frail Options
61.9-month (>5.1 yr) median PFS · 92.9% response
Omits bortezomib (V) · Ideal for diabetic numbness
41–52.6 mo PFS when Dara/Isa is unavailable
Organ Swaps & Support
Use cyclophosphamide bridge → switch to Dara-VRd
Choose Dara-Rd or carfilzomib (KRd) to save nerves
Use Dara-VRd, Isa-VRd, or Dara-Rd (no carfilzomib)
Key Takeaways & Next Steps
- Start with your strongest matched combination: For most fit patients, a 4-drug quadruplet (Dara-VRd or Isa-VRd) gives the highest probability of reaching deep, multi-year MRD-negative remission.
- Match the drugs to your body, not just the textbook: Let your baseline kidney labs, nerve health, heart history, and frailty score guide whether you need Dara-Rd, steroid-sparing Dara-R, or a Dara-VCd kidney bridge.
- Never skip supportive care: Pair your regimen from Day 1 with extended red-blood-cell typing (before anti-CD38 antibodies), shingles prevention, clot prophylaxis, and bone strengtheners.
Partnering closely with your hematologist-oncologist ensures your frontline regimen attacks the myeloma aggressively while keeping your daily life comfortable and safe.
Next Steps & Related Decision Guides
- Stem Cell Collection & Transplant Planning: If you are eligible for stem cell harvest after 3 to 4 cycles of induction, explore our Autologous Stem Cell Transplant Guide.
- Long-Term Maintenance & Stepping Down Therapy: To learn how single-drug or dual-drug maintenance works after induction and when MRD-guided de-escalation is considered, read our Maintenance Therapy Guide.
- Managing Side Effects & Protecting Your Kidneys and Bones: Review practical dose-adjustment and supportive rules in our Treatment Side Effects Guide, Renal Protection Guide, and Bone Health & Lesion Management.
- Clinical Trials Overview: Before starting treatment, learn how Phase 1 to 3 studies work in our Clinical Trials Overview or explore the CMDN Clinical Trials Navigator.
5 Questions to Ask Your Doctor
- Four Drugs vs. Three Drugs: "Based on my overall fitness and health profile, am I a better candidate for a 4-drug regimen (Dara-VRd or Isa-VRd) or a 3-drug regimen (Dara-Rd)?"
- Protecting My Nerves, Heart, and Kidneys: "Do any of my existing conditions (like diabetes, tingling fingers/toes, blood pressure, or kidney numbers) mean we should adjust bortezomib, lenalidomide, or dexamethasone?"
- Once-Weekly Subcutaneous Schedule: "If my plan includes bortezomib (V), will I receive it once a week as a subcutaneous shot under the skin?"
- Stem Cell Harvest Timing: "If I might want a stem cell transplant now or in the future, will we collect and freeze my stem cells after 3 to 4 cycles?"
- Supportive Medications & Blood Typing: "Have we ordered my baseline extended red-blood-cell typing before starting daratumumab/isatuximab, and do I have my prescriptions for shingles and blood-clot prevention?"
References
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma, Version 2.2027 (2026). Available at: https://www.nccn.org
- Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025.
- Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (PERSEUS). N Engl J Med. 2024;390(4):301-313.
- Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma (CEPHEUS). Nat Med. 2025.
- Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (IMROZ). N Engl J Med. 2024;391(17):1597-1609.
- Goldschmidt H, Mai EK, Bertsch U, et al. Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed, Transplant-Eligible Multiple Myeloma (GMMG-HD7). Lancet Haematol / J Clin Oncol. 2022-2024.
- Facon T, Moreau P, Weisel K, et al. Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (MAIA): Long-Term Survival Outcomes. Leukemia. 2025;39(4).
- Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood. 2023-2024.
This clinical decision guide is synthesized from international consensus guidelines and peer-reviewed literature for educational purposes only. It does not substitute for professional medical care. Consult your treating hematology-oncology team regarding diagnostic and treatment decisions.
CMDN Care · Myeloma Companion
Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.
Open CMDN CareHow CMDN Care worksSign in with Google or a secure email code.
Lab report OCR
Review results extracted from your reports.
Biomarker trends
Keep follow-up results in one place.
Visit preparation
Bring your questions to your care team.
FAQs
- What is the difference between Dara-VRd and Isa-VRd, and which one is better?
- Both Dara-VRd and Isa-VRd are Category 1 preferred 4-drug regimens with nearly identical efficacy, helping 60% to 75%+ of patients reach Minimal Residual Disease (MRD) negativity. The main practical difference is how the anti-CD38 antibody is given: daratumumab (Dara) is a quick 3-to-5-minute injection under the belly skin, whereas isatuximab (Isa) is given as an intravenous (IV) infusion.
- Why did my doctor start me on VCd or Dara-VCd in the hospital instead of Dara-VRd?
- Starting with VCd or Dara-VCd (using cyclophosphamide instead of lenalidomide) is smart kidney protection whenever baseline serum creatinine is elevated (> 2.0 mg/dL or > 177 μmol/L) or while waiting 1 to 2 weeks for oral lenalidomide insurance approval. Once your kidney function stabilizes, your doctor can smoothly switch you to Dara-VRd in Cycle 2 or 3.
- If I start a 4-drug regimen like Dara-VRd without a transplant, do I take all 4 drugs forever?
- No. Even if you do not undergo a stem cell transplant, you only receive all 4 drugs during the initial 6 to 8 induction cycles (about 6 months). After that, the bortezomib injections and dexamethasone steroids are stopped or tapered, and you transition to a much simpler long-term maintenance routine.
- Why do I need a special blood-bank test before starting daratumumab or isatuximab?
- Because red blood cells carry a small amount of CD38 on their surface, daratumumab and isatuximab can cause false-positive results on routine blood-transfusion crossmatching for up to 6 months after your last dose. Completing an extended red-blood-cell typing test before Dose 1 and carrying a wallet alert card ensures any hospital can quickly match safe blood for you if you ever need a transfusion.
- What happens during the very first dose of daratumumab or isatuximab?
- About 20% to 35% of patients experience a mild, flu-like reaction during Dose 1 only—such as a stuffy nose, scratchy throat, mild chills, or a low fever. Your nurse will give you preventive medicines (acetaminophen, an antihistamine, and dexamethasone) beforehand, and reactions drop below 2% from Dose 2 onward.
- Can my doctor lower my dexamethasone steroid dose if it causes severe insomnia or high blood sugar?
- Yes. Standard dexamethasone is 40 mg once weekly (or automatically lowered to 20 mg once weekly if you are over age 75). For frail or older patients, the IFM2017-03 trial proved that stopping dexamethasone completely after just 2 cycles (the Dara-R regimen) keeps remission over 4.4 years while eliminating long-term steroid side effects.
Related reading
References used for this guide
- NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (Version 2.2027)
- EHA-EMN Evidence-Based Guidelines for Diagnosis, Treatment and Follow-Up of Multiple Myeloma (Nat Rev Clin Oncol)
- PERSEUS Phase 3 Trial: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Myeloma (N Engl J Med)
- CEPHEUS Phase 3 Trial: Daratumumab-VRd in Transplant-Ineligible or Deferred Myeloma (Nat Med)
- IMROZ Phase 3 Trial: Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Myeloma (N Engl J Med)
- MAIA Phase 3 Trial: Long-Term Outcomes of Daratumumab-Lenalidomide-Dexamethasone (Leukemia)
for their academic support:
for myeloma patients globally